BURLINGAME, Calif., Jan. 24 BioSeek, Inc., a leader inapplying integrated human biology systems for developing new therapeutics,announced today that it has entered into a collaboration agreement withDainippon Sumitomo Pharma Co. (DSP), a global biopharmaceutical leader basedin Japan. Under the collaboration, BioSeek will apply its BioMAP(R) Systems tosupport compound differentiation, lead development, and drug candidateselection activities for DSP's discovery programs in the fields ofinflammation and metabolic diseases.
"We are excited to be working closely with DSP, a well respected andinnovative global company, and look forward to supporting their discoveryefforts," commented Michael C. Venuti, Ph.D., CEO of BioSeek. "Thiscollaboration leverages our technology platform's power in addressing keydecision points in the discovery process, making it extremely valuable topartners such as DSP."
"The BioMAP(R) platform represents a very compelling approach to applyinghuman systems biology to pharmaceutical research and development," stated Dr.Yuichi Yokoyama, Executive Director at DSP. "BioMAP(R) Systems deliverotherwise difficult-to-obtain human biological information, which will help usprioritize leads and candidates."
CTC Laboratory Systems Corporation, a subsidiary of Itochu Techno-Solutions Corporation, assisted with the closing of this agreement.
BioMAP(R) Systems are a series of human primary cell-based assay systemsdesigned to replicate the intricate cell and pathway interactions present inhuman disease biology. Depending on their mechanism of action, compoundsinduce specific patterns of changes in these systems (BioMAP profiles) thatcan be compared to a large number of reference profiles in BioSeek's database.BioMAP profiling provides early insight into human pharmacological propertiesof compounds including in-depth characterization of biological drug function,on- and off-target activities, and biomarker identification.
BioSeek is improving the success rate of pharmaceutical research anddevelopment by integrating human biology from the early stages of drugdiscovery onward. BioSeek is using BioMAP(R) Systems platform for the internaldiscovery and development of new drug candidates in the fields ofinflammation, cardiovascular diseases, autoimmune diseases, and relatedindications. BioSeek is also leveraging BioMAP(R) Systems technology incollaborations to enhance the productivity of its pharmaceutical partners'pipelines. For more information, go to www.bioseekinc.com.
About Dainippon Sumitomo Pharma Co.
Dainnipon Sumitomo Pharma Co.'s Corporate Mission is to broadly contributeto society through value creation based on innovative research and developmentactivities for the betterment of healthcare and fuller lives of peopleworldwide. For more information, go to http://www.ds-pharma.co.jp/english.
About CTC Laboratory Systems Corporation
CTC Laboratory Systems Corporation (Tokyo, Japan), a subsidiary of ItochuTechno-Solutions Corporation, is Japan's leading provider of total solutionsfrom target ID/VD to clinical trials for pharmaceuticals, and a variety ofsolutions for the chemical and food processing industries, as well as for lifesciences research institutions. Additional information on CTCLS can be foundat http://www.ctcls.co.jp.BioSeek Contacts: BioSeek, Inc. Michael Venuti, Ph.D. CEO Tel: 650.552.0754 MacDougall Biomedical Communications Jennifer Greenleaf Tel: 781.235.3060
SOURCE BioSeek, Inc.